Cutaneous Adverse Reactions Associated with Epidermal Growth Factor Receptor Inhibitors.
- Author:
Hyun Jae LEE
1
;
Hyun Soo SIM
;
Jong Keun SEO
;
Deborah LEE
;
Ho Suk SUNG
Author Information
1. Department of Dermatology, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea. btyouth@naver.com
- Publication Type:Original Article
- Keywords:
Cetuximab;
Epidermal growth factor receptor;
Erlotinib;
Gefitinib;
Papulopustular eruption
- MeSH:
Antibodies, Monoclonal, Humanized;
Benzoyl Peroxide;
Clindamycin;
Compliance;
Emollients;
Epidermal Growth Factor;
Histamine Antagonists;
Humans;
Incidence;
Medical Records;
Minocycline;
Paronychia;
Quinazolines;
Receptor, Epidermal Growth Factor;
Steroids;
Tetracycline;
Cetuximab;
Erlotinib Hydrochloride
- From:Korean Journal of Dermatology
2011;49(2):131-140
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Cutaneous adverse reactions are often observed during chemotherapy with epidermal growth factor receptor (EGFR) inhibitors including papulopustular eruptions, xerosis and paronychia. OBJECTIVE: To investigate and compare the cutaneous adverse reactions induced by EGFR inhibitors including erlotinib, gefitinib and cetuximab which have commonly been used as chemotherapeutic agents in Korea. METHODS: We reviewed cutaneous adverse effects through the medical records and clinical photographs of 43 Korean patients who had been treated with erlotinib, gefitinib or cetuximab at Pusan Paik Hospital between June 2003 and January 2010. RESULTS: Papulopustular eruptions occurred in 28 patients (65.1%); they were easily controlled by topical benzoyl peroxide, clindamycin and a retinoid, or by oral minocycline and tetracycline. There were no significant differences in incidence, duration and severity grades of papulopustular eruptions among EGFR inhibitors. In contrast to previous studies, the frequency and severity of papulopustular eruptions were not significantly correlated with treatment responses to EGFR inhibitors. Xerosis appeared in 14 patients (41%), and was easily controlled by topical emollients and steroids, and by systemic steroids and antihistamines. Paronychia occurred in 8 patients (18.6%) and were controlled by conservative treatments. CONCLUSION: Papulopustular eruptions, xerosis and paronychia are common cutaneous adverse reactions associated with EGFR inhibitors and there are no significant differences in adverse cutaneous reactions among EGFR inhibitors. As these cutaneous adverse reactions are relatively easily controlled with treatment, it will be helpful to detect and treat these adverse reactions early, including reassuring the patients, which should increase compliance of patients during treatment with EGFR inhibitors.
